Lapatinib and Temozolomide for the Treatment of Progressive Brain Disease in HER-2 Positive Breast Cancer

Patients selection criteria: * age 18 - 70 years * Women with cytologically or histologically proven metastatic breast cancer with recurrent / progressive brain metastases evaluable by MRI, after standard treatment with surgery (at least 3 weeks prior) or WBRT (at least 3 weeks prior) or stereotactic RT (at least 1 week prior); or otherwise deemed as unsuitable for standard treatment in the first instance * Known HER-2 positive status (immunohistochemistry (IHC) 3+ Fluorescence In Situ Hybridization (FISH) positive ) * Previous chemotherapy (adjuvant and metastatic regimens) allowed * Previous treatment with trastuzumab allowed (Trastuzumab to be discontinued prior to study entry) * At least one measurable lesion in the brain, defined as any lesion \>5mm in longest dimension on T1-weighted, gadolinium-enhanced MRI * Expected life-expectancy of more than 3 months * ECOG performance status of 0, 1 or 2 * Adequate bone marrow, renal and hepatic functionsLVEF * LVEF 50% measured by echocardiography or MUGA scan * Concomitant corticosteroids and anti-convulsants for symptomatic brain metastases are allowed